Transient effectiveness of vitamin D2 therapy in pediatric cystic fibrosis patients

被引：22

作者：

Green, Deanna M. ^{[1
]}

Leonard, Amanda R. ^{[1
]}

Paranjape, Shruti M. ^{[1
]}

Rosenstein, Beryl J. ^{[1
]}

Zeitlin, Pamela L. ^{[1
]}

Mogayzel, Peter J., Jr. ^{[1
]}

机构：

[1] Johns Hopkins Univ Hosp, Eudowood Div Pediat Resp Sci, Johns Hopkins Med Inst, Baltimore, MD 21287 USA

来源：

JOURNAL OF CYSTIC FIBROSIS | 2010年 / 9卷 / 02期

关键词：

Cystic fibrosis; Vitamin D; Bone health; SERUM 25-HYDROXYVITAMIN D; D DEFICIENCY; D INSUFFICIENCY; BONE HEALTH; CHILDREN; ADULTS; PREVALENCE; CHOLECALCIFEROL; ERGOCALCIFEROL; PREVENTION;

D O I：

10.1016/j.jcf.2010.01.002

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Background: The effectiveness of current treatment recommendations for vitamin D insufficiency in children with CF is unknown. Therefore, we assessed the effectiveness of vitamin D-2 50,000 TU once daily for 28 days for vitamin D insufficiency. Methods: Retrospective chart review of pediatric CF patients from 2006-2008. Vitamin D-2 50,000 IU daily for 28 days was given to patients with 25-OHD <30 ng/mL and repeat 25-OHD levels were obtained after completion of therapy. Results: One hundred forty-seven levels from 97 individuals were assessed. Success of treatment was 54% (n=80/147). Seventeen of 39 patients (43%) followed for an additional 6-18 months were able to maintain levels of >= 30 ng/mL. Conclusions: Vitamin D2 50,000 IU daily for 28 days was effective in correcting vitamin D insufficiency in approximately 50% of subjects. However, almost half of successfully treated patients were unable to maintain normal 25-OHD levels >6 months after completion of therapy, implying that this effect is transient. (C) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

引用

页码：143 / 149

页数：7

共 35 条

[1] Consensus statement: Guide to bone health and disease in cystic fibrosis [J].